OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Investor presentation and Confirmation of AGM
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, provides the following details on the Investor presentation and Company's Annual General Meeting ("AGM").
Investor presentation
Jag Grewal (CEO) and Chris Lea (CFO) will provide a live presentation covering the preliminary results, which were issued yesterday, via the Investor Meet Company platform on Wednesday 14 September 2022 at 12pm.
The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group plc via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow Omega Diagnostics Group plc on the Investor Meet Company platform will automatically be invited.
Annual General Meeting
The Company confirms it will host its AGM at Poets House, St Mary's Street, Ely, CB7 4EY on Wednesday 26 October 2022 at 11.00am.
Contacts:
Omega Diagnostics Group PLC | |||
Jag Grewal, Chief Executive Officer | via Walbrook PR | ||
Chris Lea, Chief Financial Officer | | ||
| | ||
finnCap Ltd | Tel: 020 7220 0500 | ||
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | | ||
Alice Lane/ Charlotte Sutcliffe (ECM) | | ||
| | ||
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com | ||
Paul McManus | Mob: 07980 541 893 | ||
Lianne Applegarth | Mob: 07584 391 303 | ||
Sam Allen | Mob: 07502 558 258 | ||
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.